Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant

Clinical Transplantation

Volumn 29, Issue 12, 2015, Pages 1105-1111

  Punzalan, Carmi Santos ^a   Barry, Curtis ^a   Zacharias, Isabel ^a   Rodrigues, Julie ^a   Mehta, Savant ^a   Bozorgzadeh, Adel ^a   Barnard, Graham F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Direct acting antiviral agents; Hepatitis C; Liver transplant; Simeprevir; Sofosbuvir

Indexed keywords

AMINOTRANSFERASE; CYCLOSPORIN; RAPAMYCIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; ANTIVIRUS AGENT; VIRUS DNA;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONFUSION; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HERPES ZOSTER; HUMAN; LIVER TRANSPLANTATION; LUNG EMBOLISM; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RECURRENT DISEASE; SIDE EFFECT; TREATMENT RESPONSE; VIRUS DETECTION; ADVERSE EFFECTS; ALLOGRAFT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; PATHOGENICITY; PROGNOSIS; VIROLOGY;

ALLOGRAFTS; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SIMEPREVIR; SOFOSBUVIR;

EID: 84983197473     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12634     Document Type: Article

References (28)

1. Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012: 32(Suppl 1): 120.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002: 122: 889.
3. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996: 334: 815.
4. Feray C, Caccamo L, Alexander GJ et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999: 117: 619.
5. Ghobrial RM, Farmer DG, Baquerizo A et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999: 229: 824; discussion 313-3.
6. Sheiner PA, Schluger LK, Emre S et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997: 3: 130.
7. Schluger LK, Sheiner PA, Thung SN et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996: 23: 971.
8. Osinusi A, Meissner EG, Lee YJ et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013: 310: 804.
9. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013: 368: 1878.
10. Asselah T. Sofosbuvir-based interferon-free therapy for patients with HCV infection. J Hepatol 2013: 59: 1342.
11. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013: 368: 1867.
12. Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014: 385: 1756.
13. Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003: 124: 642.
14. Carrion JA, Navasa M, Garcia-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007: 132: 1746.
15. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008: 14(Suppl 2): S58.
16. Bzowej N, Nelson DR, Terrault NA et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011: 17: 528.
17. Angelico M, Petrolati A, Lionetti R et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007: 46: 1009.
18. Burton JR Jr, O'Leary JG, Verna EC et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014: 61: 508.
19. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013: 33(Suppl 1): 56.
20. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002: 36: S114.
21. Yoshida EM, Sulkowski MS, Gane EJ et al. Concordance of sustained virologic response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015: 5: 41.
22. Bernstein DA, Mangia A, Yang JC et al. Concordance batween SVR4, SVR12 and SVR24 in genotype I HCV infected patients who received all oral fixed-dose combination of Ledipasvir/Sofosbuvir with or without ribavirin in phase 3 clinical trials. Hepatology 2014: 60(Suppl. 1142A): abstract.
23. Sulkowski MS, Rodriguez-Torres M, Reddy KR et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV GT 1, 2, or 3. Hepatology 2012: 56(Suppl. LB-02): abstract.
24. Zeuzem S, Berg T, Gane E et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014: 146: 430.
25. Ripper SJ, Holt EW, Cooper S et al. Simeprevir plus sofosbuvir for patients with recurrence of genotype 2 hepatitis C infection after liver transplant. Hepatology 2014: 60(Suppl. 684A): abstract.
26. Ford RM, Pillai A, Cheng N et al. Post liver transplant treatment of hepatitis C with a combination of sofosbuvir, simeprevir, +/- ribavirin at a high volume academic transplant center. Hepatology 2014: 60(Suppl. 701A): abstract.
27. Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014: 60: 8728.
28. Zimner-Rapuch S, Janus N, Deray G, Launay-Vacher V. New therapies for hepatitis C: considerations in patients with renal impairment. Drugs 2014: 74: 1307.